Effects of MAO inhibition and a combination of minor alkaloids, β-carbolines, and acetaldehyde on nicotine self-administration in adult male rats

Drug and Alcohol Dependence

Volumn 155, Issue , 2015, Pages 243-252

  Smith, Tracy T ^a   Schaff, Matthew B ^b   Rupprecht, Laura E ^b   Schassburger, Rachel L ^b   Buffalari, Deanne M ^b   Murphy, Sharon E ^c   Sved, Alan F ^a,b   Donny, Eric C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Monoamine oxidase inhibition; Nicotine; Non nicotine tobacco constituents; Regulatory science; Self administration; Tobacco policy

Indexed keywords

ACETALDEHYDE; ALKALOID DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); ANABASINE; ANATABINE; BETA CARBOLINE; COTININE; HARMAN; MYOSMINE; NICOTINE; NORNICOTINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; ALKALOID; CARBOLINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SELF ADMINISTRATION; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SMOKING; TOBACCO DEPENDENCE; ANIMAL; DOSE RESPONSE;

ACETALDEHYDE; ALKALOIDS; ANIMALS; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MONOAMINE OXIDASE INHIBITORS; NICOTINE; RATS; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; TRANYLCYPROMINE;

EID: 84941932500     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.07.002     Document Type: Article

References (45)

1. Abu Ghazaleh H., Lalies M.D., Nutt D.J., Hudson A.L. The modulatory action of harmane on serotonergic neurotransmission in rat brain. Brain Res. 2015, 1597:57-64. 10.1016/j.brainres.2014.11.056.
2. Arib O., Rat P., Molimard R., Chait A., Faure P., de Beaurepaire R. Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons. Eur. J. Pharmacol. 2010, 629:47-52. 10.1016/j.ejphar.2009.12.012.
3. Arnold M.M., Loughlin S.E., Belluzzi J.D., Leslie F.M. Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine. Neuropharmacology 2014, 85:293-304. 10.1016/j.neuropharm.2014.05.035.
4. Bardo M.T., Green T.A., Crooks P.A., Dwoskin L.P. Nornicotine is self-administered intravenously by rats. Psychopharmacology (Berl.) 1999, 146:290-296.
5. Barrett S.T., Bevins R.A. A quantitative analysis of the reward-enhancing effects of nicotine using reinforcer demand. Behav. Pharmacol. 2012, 23:781-789. 10.1097/FBP.0b013e32835a38d9.
6. Belluzzi J.D., Wang R., Leslie F.M. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005, 30:705-712. 10.1038/sj.npp.1300586.
7. Berlin I., Said S., Spreux-Varoquaux O., Olivares R., Launay J.M., Puech A.J. Monoamine oxidase A and B activities in heavy smokers. Biol. Psychiatry 1995, 38:756-761. 10.1016/0006-3223(95)00084-4.
8. Brennan K.A., Crowther A., Putt F., Roper V., Waterhouse U., Truman P. Tobacco particulate matter self-administration in rats: differential effects of tobacco type. Addict. Biol. 2013, 20:227-235.
9. Brennan K.A., Putt F., Truman P. Nicotine-, tobacco particulate matter- and methamphetamine-produced locomotor sensitisation in rats. Psychopharmacology (Berl.) 2013, 228:659-672. 10.1007/s00213-013-3071-3.
10. Caggiula A.R., Donny E.C., Palmatier M.I., Liu X., Chaudhri N., Sved A.F. The role of nicotine in smoking: a dual-reinforcement model. Nebraska Symposium on Motivation: The Motivational Impact of Nicotine and its Role in Tobacco Use 2009, vol. 55:91-109. Springer Science+Business Media, New York, NY.
11. Caine S.B., Collins G.T., Thomsen M., Wright C., Lanier R.K., Mello N.K. Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine in male rodents. Exp. Clin. Psychopharmacol. 2014, 22:9-22. 10.1037/a0035749.
12. Clemens K.J., Caille S., Stinus L., Cador M. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int. J. Neuropsychopharmacol. 2009, 12:1355-1366. 10.1017/S1461145709000273.
13. Cohen A., Koob G.F., George O. Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence. Neuropsychopharmacology 2012, 37:2153-2160. 10.1038/npp.2012.67.
14. Cohen A., Soleiman M.T., Talia R., Koob G.F., George O., Mandyam C.D. Extended access nicotine self-administration with periodic deprivation increases immature neurons in the hippocampus. Psychopharmacology (Berl.) 2015, 232:453-463. 10.1007/s00213-014-3685-0.
15. Costello M.R., Reynaga D.D., Mojica C.Y., Zaveri N.T., Belluzzi J.D., Leslie F.M. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology 2014, 39:1843-1851. 10.1038/npp.2014.31.
16. DeNoble V.J., Mele P.C. Behavioral Pharmacology Annual Report. Philip Morris Tobacco Resolution, Bates Number 20605661 1983, http://www.pmdocs.com/getallimg.asp?if=avpidx%26DOCID=1003060364/0441.
17. Depoortere R.Y., Li D.H., Lane J.D., Emmett-Oglesby M.W. Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. Pharmacol. Biochem. Behav. 1993, 45:539-548.
18. Donny E.C., Chaudhri N., Caggiula A.R., Evans-Martin F.F., Booth S., Gharib M.A., Clements L.A., Sved A.F. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl.) 2003, 169:68-76. 10.1007/s00213-003-1473-3.
19. Donny E.C., Taylor T.G., Lesage M.G., Levin M., Buffalari D.M., Joel D., Sved A.F. Impact of tobacco regulation on animal research: new perspectives and opportunities. Nicotine Tob. Res. 2012, 10.1093/ntr/nts162.
20. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R.R., Schlyer D.J., Zezulkova I., Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14065-14069.
21. Guillem K., Vouillac C., Azar M.R., Parsons L.H., Koob G.F., Cador M., Stinus L. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J. Neurosci. 2005, 25:8593-8600. 10.1523/JNEUROSCI.2139-05.2005.
22. Guillem K., Vouillac C., Azar M.R., Parsons L.H., Koob G.F., Cador M., Stinus L. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur. J. Neurosci. 2006, 24:3532-3540. 10.1111/j.1460-9568.2006.05217.x.
23. Harris A.C., Stepanov I., Pentel P.R., Lesage M.G. Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in rats. Psychopharmacology (Berl.) 2012, 220:565-576. 10.1007/s00213-011-2514-y.
24. Harris A.C., Tally L., Schmidt C.E., Muelken P., Stepanov I., Saha S. Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation. Drug Alcohol Depend. 2015, 147:60-67. 10.1016/j.drugalcdep.2014.12.015.
25. Herraiz T. Relative exposure to beta-carbolines norharman and harman from foods and tobacco smoke. Food Addit. Contam. 2004, 21:1041-1050. 10.1080/02652030400019844.
26. Herraiz T., Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. 2005, 326:378-386. 10.1016/j.bbrc.2004.11.033.
27. Herraiz T., Guillen H., Aran V.J. Oxidative metabolism of the bioactive and naturally occurring beta-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes. Chem. Res. Toxicol. 2008, 21:2172-2180. 10.1021/tx8002565.
28. Hoffman A.C., Evans S.E. Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob. Res. 2013, 15:622-632. 10.1093/ntr/nts192.
29. Hursh S.R., Silberberg A. Economic demand and essential value. Psychol. Rev. 2008, 115:186-198. 10.1037/0033-295X.115.1.186.
30. Lewis A., Miller J.H., Lea R.A. Monoamine oxidase and tobacco dependence. Neurotoxicology 2007, 28:182-195. 10.1016/j.neuro.2006.05.019.
31. Liu B., Chen C., Wu D., Su Q. Enantiomeric analysis of anatabine, nornicotine and anabasine in commercial tobacco by multi-dimensional gas chromatography and mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 865:13-17. 10.1016/j.jchromb.2008.01.034.
32. Lotfipour S., Arnold M.M., Hogenkamp D.J., Gee K.W., Belluzzi J.D., Leslie F.M. The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition. Neuropharmacology 2011, 61:95-104. 10.1016/j.neuropharm.2011.03.007.
33. Palmatier M.I., Evans-Martin F.F., Hoffman A., Caggiula A.R., Chaudhri N., Donny E.C., Sved A.F. Dissociating the primary reinforcing and reinforcement-enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental reinforcers. Psychopharmacology (Berl.) 2006, 184:391-400. 10.1007/s00213-005-0183-4.
34. Rodgman A., Perfetti T.A. The Chemical Components of Tobacco and Tobacco Smoke 2013, CRC Press, Taylor and Francis Group, LLC, Boca Raton, FL.
35. Smith T.T., Levin M.E., Schassburger R.L., Buffalari D.M., Sved A.F., Donny E.C. Gradual and immediate nicotine reduction result in similar low-dose nicotine self-administration. Nicotine Tob. Res. 2013, 15:1918-1925. 10.1093/ntr/ntt082.
36. Smith T.T., Schassburger R.L., Buffalari D.M., Sved A.F., Donny E.C. Low-dose nicotine self-administration is reduced in adult male rats naive to high doses of nicotine: implications for nicotine product standards. Exp. Clin. Psychopharmacol. 2014, 22:453-459. 10.1037/a0037396.
37. Smith T.T., Sved A.F., Hatsukami D.K., Donny E.C. Nicotine reduction as an increase in the unit price of cigarettes: a behavioral economics approach. Prev. Med. 2014, 10.1016/j.ypmed.2014.07.005.
38. Stolerman I.P., Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology (Berl.) 1995, 117:2-10. discussion 14-20.
39. Takayama S., Uyeno E.T. Intravenous self-administration of ethanol and acetaldehyde by rats. Yakubutsu Seishin Kodo 1985, 5:329-334.
40. Touiki K., Rat P., Molimard R., Chait A., de Beaurepaire R. Harmane inhibits serotonergic dorsal raphe neurons in the rat. Psychopharmacology (Berl.) 2005, 182:562-569. 10.1007/s00213-005-0118-0.
41. USDHHS How Tobacco Smoking Causes Disease: The Biological And Behavioral Basis For Smoking-Attributable Disease: A Report Of The Surgeon General (Executive Summary) 2010, USDHHS, Washington, DC.
42. Villegier A.S., Belluzzi J.D., Leslie F.M. Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self-administration. Synapse 2011, 65:479-489. 10.1002/syn.20864.
43. Villegier A.S., Lotfipour S., McQuown S.C., Belluzzi J.D., Leslie F.M. Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology 2007, 52:1415-1425. 10.1016/j.neuropharm.2007.02.001.
44. West R. Nicotine addiction: a re-analysis of the arguments. Psychopharmacology (Berl.) 1992, 108:408-410. discussion 411-406.
45. Wu W., Ashley D.L., Watson C.H. Determination of nicotine and other minor alkaloids in international cigarettes by solid-phase microextraction and gas chromatography/mass spectrometry. Anal. Chem. 2002, 74:4878-4884.